Skip to main content
    K

    Kyverna Therapeutics, Inc. Common Stock (KYTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.68
    -0.08 (-1.47%)

    Market Cap: $351.58M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(8/11)
    Avg Surprise
    -63.71%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.69
    Range$-0.77 - $-0.65
    5 analysts
    EPS Revisions
    3
    0
    7d
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.74+6.4%
    60d ago$-0.74+6.4%
    30d ago$-0.690.0%
    7d ago$-0.690.0%
    Current$-0.69
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-0.92 - $-0.52
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-0.69---
    Jun 26
    Reported Aug 12
    		$-0.63$-0.67+5.97%Beat+35.1%
    Mar 26
    Reported May 12
    		$-0.66$-0.73+10.06%Beat+36.2%
    Dec 25
    Reported Mar 26
    		$-0.80$-0.86+6.98%Beat+7.8%
    Sep 25
    Reported Nov 12
    		$-0.85$-0.95+10.53%Beat-6.2%
    Jun 25
    Reported Aug 12
    		$-0.97$-1.04+6.73%Beat-44.8%
    Mar 25
    Reported May 13
    		$-1.03$-1.00-3.00%Miss+8.0%
    Dec 24
    Reported Mar 27
    		$-0.87$-0.95+8.65%Beat+96.8%
    Sep 24
    Reported Nov 13
    		$-0.80$-0.80+0.00%Beat-
    Jun 24
    Reported Aug 12
    		$-0.67$-0.68+1.47%Beat-
    Mar 24
    Reported May 14
    		$-1.12$-0.96-16.67%Miss-
    Dec 23
    Reported Feb 8
    		$-26.86$-3.23-731.58%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.94EV/EBITDAN/A
    Price/FCF-2.16xFCF Yield-46.28%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-87.20%ROIC-65.96%
    Financial Health
    Debt/Equity0.15xInterest Coverage-88.78x
    Current Ratio9.06xQuick Ratio9.06x
    Trading Statistics
    Beta2.06Avg Volume1.02M
    52-Week High$13.6752-Week Low$5.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.16
    SMA 20$6.59
    SMA 50$7.49
    SMA 200$8.27
    EMA 10$6.18
    EMA 20$6.54
    EMA 50$7.18
    EMA 200$7.58

    MACD

    Line: -0.45Signal: -0.41Hist: -0.04

    ADX

    ADX: 18.9+DI: 15.1-DI: 28.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$6.80

    Bollinger Bands

    Upper Band$7.58
    Lower Band$5.60
    %B Position3000%(Upper)
    Band Width0.04

    RSI (14-Day)

    Oversold
    27.5

    Momentum Oscillators

    Stoch %K6.2
    Stoch %D11.1
    Williams %R-95.0
    ROC (10d)-16.4%
    Momentum-1.11
    CCI (20d)-145.2
    MFI (14d)19.2

    Volatility Measures

    ATR (14d)$0.39(6.9%)
    StdDev (20d)0.49
    Hist Vol48.9%(High)

    Volume Flow

    VWAP$5.71
    OBV30.9M
    AD Line-32.4M
    CMF (20d)-0.240

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio1.2x
    VWMA (20d)$6.60

    Pivot Points

    R3$6.46
    R2$6.31
    R1$6.04
    Pivot Point$5.90
    S1$5.63
    S2$5.48
    S3$5.21

    Advanced Oscillators

    TSI-35.11
    Ultimate Osc32.5
    KST-195.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.02M$0$0$0$0$0
    Cost of Revenue$0$0$368,000$0$0$0$563,000$0$0$0$17.16M$0
    Gross Profit$0$0$-368,000$0$0$0$-563,000$0$0$0$-17,163,000$0
    Operating Expenses$39.56M$41.37M$39.28M$38.73M$44.41M$47.41M$41.04M$38.77M$33.44M$29.36M$21.38M$16.28M
    R&D$24.79M$30.07M$30.01M$30.46M$35.82M$37.43M$33.48M$29.19M$27.32M$22.48M$17.16M$13.64M
    SG&A$14.77M$11.29M$9.27M$8.27M$8.59M$9.97M$7.56M$9.58M$6.11M$6.88M$4.21M$2.64M
    Operating Income$-39,556,000$-41,367,000$-39,282,000$-38,727,000$-44,410,000$-47,408,000$-41,041,000$-38,770,000$-33,435,000$-29,358,000$-21,377,000$-16,282,000
    Interest Income$1.93M$2.33M$1.91M$2.00M$2.36M$2.83M$3.58M$4.36M$4.69M$2.73M$789,000$880,000
    Interest Expense$674,000$667,000$443,000$7,000$14,000$25,000$27,000$32,000$39,000$44,000$47,000$50,000
    Income Before Tax$-38,319,000$-39,728,000$-37,804,000$-36,787,000$-42,081,000$-44,635,000$-37,489,000$-34,492,000$-28,803,000$-26,693,000$-20,667,000$-15,465,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-38,319,000$-39,728,000$-37,804,000$-36,787,000$-42,081,000$-44,635,000$-37,489,000$-34,492,000$-28,803,000$-26,693,000$-20,667,000$-15,465,000
    EBITDA$-39,330,000$-41,767,000$-40,266,000$-39,932,000$-45,759,000$-49,044,000$-42,710,000$-41,150,000$-35,183,000$-29,182,000$-21,552,000$-16,297,000
    EBIT$-39,574,000$-41,388,000$-39,266,000$-38,780,000$-44,431,000$-47,435,000$-41,037,000$-38,815,000$-33,458,000$-29,384,000$-21,409,000$-16,295,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KYTX

    News

    Kyverna Therapeutics Q3 2026 Earnings Date and Estimates

    Kyverna Therapeutics (NASDAQ:KYTX) is projected to report its Q3 2026 earnings on Wednesday, November 11, 2026, with an accompanying conference call on November 12, 2026...

    MarketBeat•10/15/26•Neutral

    Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

    Kyverna Therapeutics will present positive clinical data for its miv-cel (mivocabtagene autoleucel, KYV-101) therapy in Stiff Person Syndrome (SPS) and progressive multiple sclerosis (MS) at MSToronto2026. The data will...

    Yahoo Finance•10/7/26•Bullish

    A cell therapy showed sustained benefit after one dose for stiff person syndrome; Kyverna will present data.

    Kyverna Therapeutics will present one-year data from its KYSA-8 Phase 2 trial of miv-cel in stiff person syndrome (SPS) at MSToronto2026...

    Stock Titan•10/7/26•Bullish

    Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Sell-Side Brokerages

    Kyverna Therapeutics (NASDAQ:KYTX) has received a "Moderate Buy" rating from sell-side brokerages, with an average 12-month price target of $29.00. The company's stock opened at $6.22, near its 52-week low...

    MarketBeat•10/3/26•Somewhat-Bullish

    Bank of America Corp DE Makes New Investment in Kyverna Therapeutics, Inc. $KYTX

    Bank of America Corp DE has acquired a new stake in Kyverna Therapeutics, purchasing 265,405 shares valued at approximately $2.365 million in the second quarter. Other institutional investors like BlackRock and AIGH...

    MarketBeat•10/1/26•Neutral

    KYTX Valuation and Fair Value

    P/E
    -1.9x
    P/FCF
    -2.2x
    P/B
    2.1x
    See GNG's fair value

    KYTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -66.0%
    ROE
    -87.2%
    FCF yield
    -46.3%

    KYTX Competitors

    CompanyTicker
    Emergent Biosolutions IncEBS
    Embecta CorpEMBC
    Fennec Pharmaceuticals IncFENC
    Opus Genetics, Inc.IRD
    Galectin Therapeutics IncGALT
    Orchestra BioMed Holdings Inc.OBIO
    Wellgistics Health, Inc. Common StockWGRX
    Semler Scientific IncSMLR

    Sector: Healthcare

    KYTX Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    2
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    KYTX Bull Case vs Bear Case

    Bull case

    • KYTX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of KYTX's analyst ratings are Buy or Strong Buy.

    KYTX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    5.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.69
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 1 down

    Frequently Asked Questions About KYTX

    Does KYTX pay dividends?

    Kyverna Therapeutics, Inc. Common Stock (KYTX) does not currently pay a regular dividend.

    What is KYTX's market cap?

    Kyverna Therapeutics, Inc. Common Stock (KYTX) has a market capitalization of $351.58M with a current stock price of $5.68.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In